Chemed (CHE)
(Delayed Data from NYSE)
$543.66 USD
-0.51 (-0.09%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $543.55 -0.11 (-0.02%) 7:58 PM ET
4-Sell of 5 4
C Value B Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$543.66 USD
-0.51 (-0.09%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $543.55 -0.11 (-0.02%) 7:58 PM ET
4-Sell of 5 4
C Value B Growth B Momentum B VGM
Zacks News
Chemed (CHE) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Chemed (CHE) closed the most recent trading day at $456.01, moving +1.3% from the previous trading session.
Chemed (CHE) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Chemed (CHE) closed the most recent trading day at $435.24, moving +1.72% from the previous trading session.
DVA vs. CHE: Which Stock Is the Better Value Option?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?
Chemed (CHE) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Chemed (CHE) closed at $456.38 in the latest trading session, marking a +0.92% move from the prior day.
Zacks.com featured highlights include: Synopsys, Tesla, Chemed, Teekay Tankers and West Pharmaceutical Services
by Zacks Equity Research
Zacks.com featured highlights include: Synopsys, Tesla, Chemed, Teekay Tankers and West Pharmaceutical Services
Buy These 5 Low Leverage Stocks to Invest Safely
by Zacks Equity Research
Debt financing is a feasible option as long as the companies succeed in generating a higher rate of return compared to the interest rate
Chemed (CHE) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Chemed (CHE) closed at $478.51 in the latest trading session, marking a -0.78% move from the prior day.
Why Is Chemed (CHE) Up 8.3% Since Last Earnings Report?
by Zacks Equity Research
Chemed (CHE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Hold on to Chemed (CHE) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Chemed (CHE) on robust segmental growth.
The Zacks Analyst Blog Highlights: Brookdale Senior Living, The Ensign Group, Amedysis and Chemed
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Brookdale Senior Living, The Ensign Group, Amedysis and Chemed
Silver Tsunami to Hit the United States: 4 Stocks in Focus
by Aparajita Dutta
There are approximately 35 million Americans aged 65 or older currently and this number is expected to double in the next 25 years.
DVA or CHE: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?
Is Chemed (CHE) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (CHE) Outperforming Other Medical Stocks This Year?
What Makes Chemed (CHE) a New Buy Stock
by Zacks Equity Research
Chemed (CHE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
DVA vs. CHE: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?
Chemed's (CHE) Q1 Earnings Beat Estimates, Margins Improve
by Zacks Equity Research
Chemed's (CHE) first-quarter 2020 results reflect strong segmental performances amid the coronavirus-led economic doldrums.
Chemed (CHE) Q1 Earnings Surpass Estimates
by Zacks Equity Research
Chemed (CHE) delivered earnings and revenue surprises of 2.22% and -1.49%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Is Chemed (CHE) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (CHE) Outperforming Other Medical Stocks This Year?
Baxter (BAX) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Baxter's (BAX) first-quarter performance is likely to reflect growth in its six global business units.
Stryker (SYK) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Stryker's (SYK) first-quarter earnings likely to reflect strong segmental performances by Medsurg and Neurotechnology & Spine.
Why Chemed (CHE) Might Surprise This Earnings Season
by Zacks Equity Research
Chemed (CHE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
What's in Store for Juniper (JNPR) This Earnings Season?
by Zacks Equity Research
Juniper's (JNPR) first-quarter 2020 performance is likely to have benefited from changes to its go-to-market structure to better align sales strategies with each of the core customer verticals.
Optical & Display Units to Hurt Corning's (GLW) Q1 Earnings
by Zacks Equity Research
Headwinds in the Optical Communications and Display Technologies business segments are likely to get reflected in Corning's (GLW) first-quarter 2020 results.
The Zacks Analyst Blog Highlights: Limelight Networks, Chemed, Cigna, CURO Group and Huron Consulting Group
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Limelight Networks, Chemed, Cigna, CURO Group and Huron Consulting Group
Edwards Lifesciences (EW) Beats on Q1 Earnings, Cuts '20 View
by Zacks Equity Research
Amid the coronavirus impact on sales, Edwards Lifesciences (EW) witnesses growth in TAVR procedures led by strong therapy adoption across all geographies, particularly in the United States.